BMP-2 mediates retinoid-induced apoptosis in medulloblastoma cells through a paracrine effect

Nature Medicine

Volumn 9, Issue 8, 2003, Pages 1033-1038

  Hallahan, Andrew R ^a,b   Pritchard, Joel I ^a   Chandraratna, Roshantha A S ^c   Ellenbogen, Richard G ^b   Geyer, J Russel ^b   Overland, Ryan P ^a   Strand, Andrew D ^a   Tapscott, Stephen J ^a   Olson, James M ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^c ALLERGAN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGN 195183; BONE MORPHOGENETIC PROTEIN 2; ISOTRETINOIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; NOGGIN; PROTEIN INHIBITOR; RETINOIC ACID; RETINOID; RETINOID DERIVATIVE; TAZAROTENE; UNCLASSIFIED DRUG;

ADOLESCENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENZYME INDUCTION; FEMALE; GENE EXPRESSION; MEDULLOBLASTOMA; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; NUDE MOUSE; PARACRINE SIGNALING; PRIORITY JOURNAL; TUMOR CELL; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; BONE MORPHOGENETIC PROTEIN RECEPTORS; BONE MORPHOGENETIC PROTEINS; BRAIN NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MEDULLOBLASTOMA; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PARACRINE COMMUNICATION; RECEPTORS, GROWTH FACTOR; RETINOIDS; TRANSFORMING GROWTH FACTOR BETA; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

ANIMALIA; MUS MUSCULUS;

EID: 0042967678     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm904     Document Type: Article

References (50)

1. Sidell, N., Altman, A., Haussler, M.R. & Seeger, R.C. Effects of retinoic acid (RA) on the growth and phenotypic expression of several human neuroblastoma cell lines. Exp. Cell. Res. 148, 21-30 (1983).
2. Matthay, K.K. et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N. Engl. J. Med. 341, 1165-1173 (1999).
3. Lin, R.J., Sternsdorf, T., Tini, M. & Evans, R.M. Transcriptional regulation in acute promyelocytic leukemia. Oncogene 20, 7204-7215 (2001).
4. Altucci, L. & Gronemeyer, H. The promise of retinoids to fight against cancer. Nat. Rev. Cancer 1, 181-193 (2001).
5. Packer, R.J., Cogen, P., Vezina, G. & Rorke, L.B. Medulloblastoma: clinical and biologic aspects. Neuro-oncology 1, 232-250 (1999).
6. Yamamoto, M., McCaffery, P. & Drager, U.C. Influence of the choroid plexus on cerebellar development: analysis of retinoic acid synthesis. Brain Res. Dev. Brain Res. 93, 182-190 (1996).
7. Chambon, P. A decade of molecular biology of retinoic acid receptors. FASEB J. 10, 940-954 (1996).
8. McBurney, M.W., Jones-Villeneuve, E.M., Edwards, M.K. & Anderson, P.J. Control of muscle and neuronal differentiation in a cultured embryonal carcinoma cell line. Nature 299, 165-167 (1982).
9. Wang, Q. et al. 1,25-dihydroxyvitamin D3 and retonic acid analogues induce differentiation in breast cancer cells with function- and cell-specific additive effects. Breast Cancer Res. Treat. 67, 157-168 (2001).
10. Chandraratna, R.A. Tazarotene - first of a new generation of receptor-selective retinoids. Br. J. Dermatol. 135 (suppl. 49), 18-25 (1996).
11. Eberhart, C.G. et al. Histopathologic grading of medulloblastomas: a Pediatric Oncology Group study. Cancer 94, 552-560 (2002).
12. Evans, A.E. et al. Antitumor activity of CEP-751 (KT-6587) en on human neuroblastoma and medulloblastoma xenografts. Clin. Cancer Res. 5, 3594-3602 (1999).
13. Johnson, A.T., Wang, L., Standeven, A.M., Escobar, M. & Chandraratna, R.A. Synthesis and biological activity of high-affinity retinoic acid receptor antagonists. Bioorg. Med. Chem. 7, 1321-1338 (1999).
14. Nie, X.F., Maclean, K.N., Kumar, V., McKay, I.A. & Bustin, S.A. ERF-2, the human homologue of the murine Tis11d early response gene. Gene 152, 285-286 (1995)
15. Johnson, B.A., Geha, M. & Blackwell, T.K. Similar but distinct effects of the tristetraprolin/TIS11 immediate-early proteins on cell survival. Oncogene 19, 1657-1664 (2000).
16. Sheikh, M.S., Hollander, M.C. & Fornance, A.J., Jr. Role of Gadd45 in apoptosis. Biochem. Pharmacol. 59, 43-45 (2000).
17. Rodriguez-Leon, J. et al. Retinoic acid regulates programmed cell death through BMP signalling. Nat. Cell Biol. 1, 125-126 (1999).
18. Ghatpande, S., Ghatpande, A., Sher, J., Zile, M.H. & Evans, T. Retinoid signaling regulates primitive (yolk sac) hematopoiesis. Blood 99, 2379-2386 (2002).
19. Caricasole, A., Ward-van Oostwaard, D., Zeinstra, L., van den Eijnden-van Raaij, A. & Mummery, C. Bone morphogenetic proteins (BMPs) induce epithelial differentiation of NT2D1 human embryonal carcinoma cells. Int. J. Dev. Biol. 44, 443-450 (2000).
20. Kawamura, C. et al. Bone morphogenetic protein-2 induces apoptosis in human myeloma cells with modulation of STAT3. Blood 96, 2005-2011 (2000).
21. Zhu, G., Mehler, M.F., Zhao, J., Yu Yung, S. & Kessler, J.A. Sonic hedgehog and BMP2 exert opposing actions on proliferation and differentiation of embryonic neural progenitor cells. Dev. Biol. 215, 118-129 (1999).
22. Goodrich, L.V. & Scott, M.P. Hedgehog and patched in neural development and disease. Neuron 21, 1243-1257 (1998).
23. Iantosca, M.R., McPherson, C.E., Ho, S.Y. & Maxwell, G.D. Bone morphogenetic proteins-2 and -4 attenuate apoptosis in a cerebellar primitive neuroectodermal tumor cell line. J. Neurosci. Res. 56, 248-258 (1999).
24. Mehler, M.F., Mabie, P.C., Zhang, D. & Kessler, J.A. Bone morphogenetic proteins in the nervous system. Trends Neurosci. 20, 309-317 (1997).
25. Song, Q., Mehler, M.F. & Kessler, J.A. Bone morphogenetic proteins induce apoptosis and growth factor dependence of cultured sympathoadrenal progenitor cells. Dev. Biol. 196, 119-127 (1998).
26. Zimmerman, L.B., De Jesus-Escobar, J.M. & Harland, R.M. The Spemann organizer signal noggin binds and inactivates bone morphogenetic protein 4. Cell 86, 599-606 (1996).
27. Smith, W.C. & Harland, R.M. Expression cloning of noggin, a new dorsalizing factor localized to the Spemann organizer in Xenopus embryos. Cell 70, 829-840 (1992).
28. Lamb, T.M. et al. Neural induction by the secreted polypeptide noggin. Science 262, 713-718 (1993).
29. McMahon, J.A. et al. Noggin-mediated antagonism of BMP signaling is required for growth and patterning of the neural tube and somite. Genes Dev. 12, 1438-1452 (1998).
30. Lim, D.A. et al. Noggin antagonizes BMP signaling to create a niche for adult neurogenesis. Neuron 28, 713-726 (2000).
31. Rosenzweig, B.L. et al. Cloning and characterization of a human type II receptor for bone morphogenetic proteins. Proc. Natl. Acad. Sci. USA 92, 7632-7636 (1995).
32. Penton, A. et al. Identification of two bone morphogenetic protein type I receptors in Drosophila and evidence that Brk25D is a decapentaplegic receptor. Cell 78, 239-250 (1994).
33. Hoodless, P.A. et al. MADR1, a MAD-related protein that functions in BMP2 signaling pathways. Cell 85, 489-500 (1996).
34. Liu, F. et al. A human Mad protein acting as a BMP-regulated transcriptional activator. Nature 381, 620-623 (1996).
35. Kimura, N., Matsuo, R., Shibuya, H., Nakashima, K. & Taga, T. BMP2-induced apoptosis is mediated by activation of the TAK1-p38 kinase pathway that is negatively regulated by Smad6. J. Biol. Chem. 275, 17647-17652 (2000).
36. Yu, L., Hebert, M.C. & Zhang, Y.E. TGF-beta receptor-activated p38 MAP kinase mediates Smad-independent TGF-beta responses. EMBO J. 21, 3749-3759 (2002).
37. Tong, L. et al. A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket. Nat. Struct. Biol. 4, 311-316 (1997).
38. Kastner, P., Mark, M. & Chambon, P. Nonsteroid nuclear receptors: what are genetic studies telling us about their role in real life? Cell 83, 859-869 (1995).
39. Maria, B.L. et al. The modulation of astrocytic differentiation in cells derived from a medulloblastoma surgical specimen. J. Neurooncol. 7, 329-338 (1989).
40. Keles, G.E., Berger, M.S., Schofield, D. & Bothwell, M. Nerve growth factor receptor expression in medulloblastomas and the potential role of nerve growth factor as a differentiating agent in medulloblastoma cell lines. Neurosurgery 32, 274-280 (1993).
41. Liu, J., Guo, L., Luo, Y., Li, J.W. & Li, H. All trans-retinoic acid suppresses in vitro growth and down-regulates LIF gene expression as well as telomerase activity of human medulloblastoma cells. Anticancer Res. 20, 2659-2664 (2000).
42. Altucci, L. et al. Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL. Nat. Med. 7, 680-686 (2001).
43. Berman, D.M. et al. Medulloblastoma growth inhibition by hedgehog pathway blockade. Science 297, 1559-1561 (2002).
44. Rostomily, R.C. et al. Expression of neurogenic basic helix-loop-helix genes in primitive neuroectodermal tumors. Cancer Res. 57, 3526-3531 (1997).
45. Farah, M.H. et al. Generation of neurons by transient expression of neural bHLH proteins in mammalian cells. Development 127, 693-702 (2000).
46. Olson, J.M. et al. NeuroD2 is necessary for development and survival of central nervous system neurons. Dev. Biol. 234, 174-187 (2001).
47. Conley, B.A. et al. Antitumor activity, distribution, and metabolism of 13-cis-retinoic acid as a single agent or in combination with tamoxifen in established human MCF-7 xenografts in mice. Cancer Chemother. Pharmacol. 43, 183-197 (1999).
48. Shalinsky, D.R, et al. Retinoid-induced suppression of squamous cell differentiation in human oral squamous cell carcinoma xenografts (line 1483) in athymic nude mice. Cancer Res. 55, 3183-3191 (1995).
49. Tomayko, M.M. & Reynolds, C.P. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother. Pharmacol. 24, 148-154 (1989).
50. Strand, A.D., Olson, J.M. & Kooperberg, C. Estimating the statistical significance of gene expression changes observed with oligonucleotide arrays. Hum. Mol. Genet. 11, 2207-2221 (2002).